“It’s all about the brain,” said Jennifer DeWolfe, D.O., professor in the UAB Department of Neurology. “Seizure manifestations are stereotyped, so the same symptoms occur with each seizure that ...

Epilepsy is a common neurological disorder that affects millions of people worldwide. Characterized primarily by seizures, epilepsy can present in a variety of ways depending on the individual and the ...

Please provide your email address to receive an email when new articles are posted on . Cannabidiol treatment was associated with median reduction of 67% to 99% in focal aware seizures. All ...

A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes for patients who continue to suffer seizures despite being on multiple ...

Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Nearly 70% had reduced seizure frequency and some patients achieved seizure freedom. Improvement was not ...

Please provide your email address to receive an email when new articles are posted on . Monthly seizure frequency percentage reduction was 68.73% for the entire study cohort. For those followed up in ...

An abnormal electrical discharge in the brain causes a seizure. There are different types, and each can cause different symptoms. A seizure may result from a medical condition or another issue, such ...

You can expect most epilepsy cases to improve with antiseizure drugs. Surgery is an option if medications do not work for your epilepsy. You may eat a ketogenic diet to help with treatment-resistant ...

Ovid Therapeutics (OVID) shares jumped over 40% premarket as the biopharmaceutical company reported favorable safety and tolerability results for the 7 mg dose of its OV329 epilepsy drug, while ...

Ovid Therapeutics Inc. (NASDAQ:OVID) said Wednesday it has raised $60 million through a private placement to support the ...

On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the ...